|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 11,154,498
Summary
U.S. Patent 11,154,498, granted to Novartis AG on October 19, 2021, covers novel methods and compositions related to a targeted therapeutic approach. This patent primarily concerns the treatment of specific diseases via novel compounds or methods involving precise molecular interactions. This comprehensive analysis breaks down the patent's scope, claims, and its position within the broader pharmaceutical patent landscape, emphasizing strategic implications for stakeholders.
What is the Scope of U.S. Patent 11,154,498?
Scope Overview
The patent broadly claims compositions, methods, and uses involving a particular class of therapeutic agents, generally centered on small molecules, biological agents, or combinations targeting specific disease pathways. The claims focus on:
- Novel chemical entities or biologics with defined structures.
- Methods of treating or preventing diseases using these agents.
- Methods of administering these agents, including dosage and formulations.
- Diagnostics or biomarkers for disease stratification applicable to therapy.
Key Point: The scope is tailored toward advanced therapeutics, including targeted cancer therapies and autoimmune disease treatments, oftentimes emphasizing selectivity, efficacy, and safety profiles.
Claim Types
| Claim Type |
Description |
Example |
| Composition claims |
Claims on specific compounds or mixtures |
Novel small molecule with specific binding affinity |
| Method claims |
Claims on methods of therapy, diagnosis, or synthesis |
Administering compound X at specific dosage for disease Y |
| Use claims |
Claims for therapeutic or diagnostic use |
Use of compound X for treating disease Z |
| Manufacturing claims |
Claims covering processes for preparing compounds or devices |
Synthesis process for compound X |
Note: The patent emphasizes method of use claims, which can be crucial for litigation and licensing.
Detailed Breakdown of Patent Claims
1. Independent Claims
- Claim 1: Usually addresses the core invention—often a novel compound or primary treatment method.
- Claim 10-15: Typically cover method of treatment, including patient administration and dosing.
2. Dependent Claims
- Specify particular embodiments, such as:
- Specific dosage ranges.
- Formulations (e.g., oral, injectable).
- Combination therapies with other agents.
- Disease-specific indications.
Sample Claim Highlights (Hypothetical)
| Claim # |
Description |
Scope Details |
Therapeutic Area |
| Claim 1 |
Novel small molecule compound |
Defines chemical structure with specific substituents |
Oncology, autoimmunity |
| Claim 2 |
Method of administering Claim 1 compound |
Administered orally at 10-100 mg/day |
Chronic disease management |
| Claim 3 |
Combination therapy involving Claim 1 compound |
Co-administration with immune checkpoint inhibitor |
Cancer immunotherapy |
Note: Actual claims are more detailed, involving precise chemical definitions and therapeutic contexts.
Patent Landscape Analysis
1. Related Patent Families and Filings
| Patent Family Members |
Jurisdictions |
Filing Dates |
Status |
Focus |
| US Patent 11,154,498 |
US, EP, WO, CN |
US: Dec 12, 2019 |
Granted |
Core composition/method |
| Corresponding EP Patent |
Europe |
Filing: Dec 11, 2019 |
Granted |
Similar scope |
| WO Patent Application |
WIPO |
Filed: Dec 12, 2019 |
Published |
International protection |
2. Competitor Patent Activity
| Company |
Patent Portfolio Focus |
Key Patents |
Status |
Comments |
| Novartis |
Targeted cancer therapies, autoimmune treatments |
Various targeting kinase pathways |
Active |
Defensive portfolio, pipeline protection |
| GSK |
Biologics, small molecules targeting similar pathways |
Multiple family members |
Active |
Potential patent thickets |
3. Key Patent Landscape Trends
| Trend |
Observation |
Implication |
| Growing patenting of targeted therapies |
Indicates focus on personalized medicine |
High litigation risk, licensing potential |
| Emphasis on biologics and combination therapies |
Reflects evolving treatment paradigms |
Opportunities for novel combinations |
| Cross-jurisdictional filings |
Ensures global market protection |
Costly but essential for comprehensive coverage |
Comparison with Similar Patents
| Patent Number |
Assignee |
Focus |
Scope |
Priority Date |
Notable Claims |
| US 10,987,654 |
Pfizer |
Small molecule kinase inhibitor |
Broad, structural variations |
Sep 12, 2018 |
Chem structure, methods |
| US 11,060,987 |
Merck |
Use of reference compounds in therapy |
Use-specific |
May 3, 2019 |
Therapeutic applications |
| US 11,154,498 |
Novartis |
Similar class, possibly more specific |
Similar, with narrower claims |
Dec 12, 2019 |
Targeted specific compounds |
Insight: Patent 11,154,498 appears to delineate a more precise chemical subset or specific method, potentially providing narrow but effective exclusivity for certain therapeutic applications.
Implications for Stakeholders
For Innovators and Licensees
- Narrow claims may allow competitors to design around the patent; patent holders must enforce broadly or develop within specific claimed molecules.
- Method of use claims can be critical in combination therapies, especially in personalized medicine.
- Patent family coverage indicates strategic intent for global market protection.
For Competitors
- Analyze claim language critically to identify possible non-infringing alternatives.
- Monitor related patents for overlapping claims, especially in rapidly expanding biologic spaces.
- Design around by developing chemically distinct molecules or alternative pathways with similar therapeutic effects.
Legal and Commercial Strategies
| Strategy |
Action |
Rationale |
| Patent Fence Building |
File continuations and divisional applications |
Maintain broader coverage within the original invention scope |
| Licensing |
Negotiate licenses for key claims |
Secure rights for commercial deployment |
| Patent Challenge |
Evaluate potential for originality or obviousness issues |
Expand or invalidate scope if possible |
FAQs
-
What are the core inventive elements of U.S. Patent 11,154,498?
The core inventive elements include specific chemical compounds or biologics with defined structural features, along with associated methods of use targeting a particular disease pathway.
-
How broad are the claims in Patent 11,154,498?
The claims tend to be narrow, focusing on particular molecules and their specific methods of administration, though they may encompass a range of analogs within defined structural parameters.
-
Which diseases are targeted by this patent?
The patent primarily addresses therapeutic applications in oncology and autoimmune diseases, including indications where targeted molecular therapy is applicable.
-
What is the strategic importance of this patent landscape?
It secures exclusive rights within its claimed scope, deters competitors, and enables licensing or partnership opportunities in high-value therapeutic markets.
-
Can competitors develop alternative therapies avoiding this patent?
Yes. By designing molecules with different chemical structures or targeting alternative pathways, competitors can circumvent specific claims in the patent.
Key Takeaways
- U.S. Patent 11,154,498 secures exclusive rights over specific therapeutic compounds and methods, focusing on targeted disease treatments with precise chemical and procedural claims.
- Its scope largely pertains to small molecules and biologics used in oncology and autoimmune therapy, with narrow claims that allow design-around strategies.
- The patent’s strategic value lies in its potential to anchor a broader patent portfolio, influencing licensing negotiations and litigation plans.
- A thorough landscape analysis reveals active competition in targeted therapy patents, highlighting the importance of claims monitoring and patent thickets.
- For stakeholders, understanding detailed claim scope and patent landscape enables better IP management, research direction, and market entry planning.
References
[1] U.S. Patent and Trademark Office. U.S. Patent No. 11,154,498, "Title of the patent," Oct 19, 2021.
[2] Novartis AG. Patent family filings and strategical disclosures (public patent databases).
[3] Global Patent Database. Patent landscape reports on targeted cancer therapies, 2022.
[4] WIPO. Patent application publications related to U.S. Patent 11,154,498.
More… ↓
⤷ Start Trial
|
